

Akums launches generic formulation to treat migraine

Migraine, a chronic neurovascular disorder affecting millions globally, is characterised by recurrent, severe headaches accompanied by nausea and sensitivity to light and sound.

[Akums Drugs & Pharmaceuticals Ltd.](#), a contract manufacturing pharmaceutical company, on Friday announced that it has launched the Lasmiditan tablet which is prescribed to treat migraine. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).

It is the generic formulation of Eli Lilly's REYVOW which is indicated for treatment of acute migraine.

Migraine, a chronic neurovascular disorder affecting millions globally, is characterised by recurrent, severe headaches accompanied by nausea and sensitivity to light and sound.

In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in [India](#), affecting an astonishing 488 million individuals.

The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.

“Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said.

News Source:

<https://www.financialexpress.com/healthcare/pharma-healthcare/akums-launches-generic-formulation-to-treat-migraine/3356483/>